Menu

Anti-CRISPR Proteins Found that Block Cas12a Nuclease

Using bioinformatics, two teams of scientists identified inhibitory proteins for Cas9’s relative.

Sep 6, 2018
Ashley Yeager

ABOVE: Inhibitors of Cas9, illustrated here, had been found previously.
© ISTOCK, MOLEKUUL

Newly identified anti-CRISPR proteins block Cas12a, a cousin of the Cas9 nuclease, both of which are widely used in genome editing, two teams of researchers report today (September 6) in Science. While past studies have identified several inhibitors of Cas9, these proteins are the first ones known to act against Cas12a. 

Both teams used bioinformatics tools to scan bacterial genomes for Cas inhibitors and came across several candidate proteins, which the researchers then tested in human cells. One of the proteins, AcrVA1, emerged as the most effective at countering Cas12a, suggesting it could become another tool to keep CRISPR gene editing in check, the scientists say.

See “CRISPR Antidotes Galore” and “Anti-CRISPR Protein Reduces Off-Target Effects

“The strategy described herein enabled the identification of many widespread anti-CRISPR proteins, which may prove useful in future anti-CRISPR discovery,” coauthor Nicole Marino of the University of California, San Francisco, and her colleagues write in their report.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.